Glucagon-like Peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation

Xiao-Yun Xie, Zhao-Hui Mo, Ke Chen, Hong-Hui He, Yan-Hong Xie

Department of Endocrinology, 3rd Xiangya Hospital, Central South University, Hunan Province, Changsha, China

Source of support: Departmental sources

Summary

Background:
Glucagon-like peptide-1 (GLP-1), released from enteroendocrine cells of the intestine, exerted cardiovascular protective effect. Circulating endothelial progenitor cells (EPCs) play an important role in maintaining endothelial integrity regulating neovascularization and reendothelialization after endothelial injury. Vascular endothelial growth factor (VEGF) is an important cytokine in the process of EPCs vascular differentiation and proliferation.

Material/Methods:
This study was designed to investigate the association between VEGF changes and the proliferation/differentiation function of EPCs in the presence of GLP-1.

Results:
We demonstrated that GLP-1 markedly enhanced the EPCs proliferation and expression of EC-specific markers, and simultaneously upregulated VEGF secretion in EPCs. Exogenous VEGF augmented EPCs proliferation/differentiation abilities in a dose-dependent manner. However, all of the beneficial effects of GLP-1 were suppressed by anti-VEGF mAb or the KDR-specific tyrosine kinase inhibitor SU1498.

Conclusions:
These findings suggest that GLP-1 improves VEGF generation, which contributed to improvement of EPCs biological function, partly by tyrosine kinase KDR. VEGF is a necessary intermediate, mediating the effects of GLP-1 on EPCs. These changes offer a novel explanation that upregulation EPCs bioactivities may be one of the mechanisms of GLP-1 cardiovascular protective effect.

key words: glucagon-like peptide-1 (GLP-1) • endothelial progenitor cells (EPCs) • VEGF
BACKGROUND

Glucagon-like peptide-1 (GLP-1), released from enteroendocrine cells of the intestine, is a regulatory factor of various cells and tissues. Recent studies showed that GLP-1 improved the vascular endothelial cell dysfunction and exerted cardiovascular protective effect [1]. Endothelial dysfunction is essentially the damage of injury-repair process homeostatic equilibrium. Circulating endothelial progenitor cells (EPCs) derived from bone marrow were isolated and characterized in 1997 [2], altering our understanding of endothelial function and new blood vessel growth. Circulating EPCs play an important role in maintaining endothelial integrity regulating neovascularization and reendothelialization after endothelial injury [3,4]. Therefore, we hypothesized that GLP-1 is involved in protection of vascular endothelium by improving the biologic function of EPCs.

EPCs share characteristics of both hematopoietic stem cells and endothelial cells, such as expression of endothelial markers and the ability to differentiate into mature endothelium [5]. Cytokines is known to participate in the process of EPCs differentiation into endothelial cells [6]. Vascular endothelial growth factor VEGF is identified as a key regulator of EPCs biuration. VEGF-induced mobilization of bone marrow-derived EPCs resulted in increased differentiated EPCs in vitro and augmented corneal neovascularization in vivo [7,8]. These findings thus establish a novel role for VEGF in postnatal neovascularization, which complements its known impact on angiogenesis. Given VEGF regulatory role in both angiogenesis and vasculogenesis in EPCs, we observe the effects of GLP-1 on biological function and VEGF generation of EPCs to explore the probable mechanism of the cardiovascular protective effect of GLP-1.

MATERIAL AND METHODS

Isolation, cultivation, and characterization of EPCs

EPCs were obtained by isolating peripheral mononuclear cells from blood of healthy volunteers by use of Ficoll density centrifugation. Recovered cells were washed twice with PBS. Unslected mononuclear cells were plated on fibronectin-coated culture dishes (Biorad; BectonDickinson Labware) at a density of 10⁶ cells/ml in Medium 199 (Invitrogen), incubated by M199 medium (Hyclone) consisting of 20% fetal bovine serum, 100 units/ml penicillin/streptomycin (Invitrogen). Three days after seeding, nonadherent cells were removed by washing with PBS, and the media were replaced. Adherent cells were identified as EPCs.

Characterization of cultured EPCs

At the end of the growth curve, cultured cells were characterized to confirm their endothelial phenotype in 6 randomly selected subjects. The cells were fixed with 4% paraformaldehyde for 30 min, then washed twice with phosphate-buffered saline (PBS) and stained with primary antibody (1:300): monoclonal antibodies against CD133/KDR. To have further methodological confirmation of the endothelial phenotype, cultured EPCs were detached CD133/CD34. Sections were incubated at 4 degrees Celsius overnight; followed by overnight incubation with secondary antibody (1:100) at 4 degrees Celsius. After washing twice with PBS, images of the stained cells were viewed with a laser scanning confocal microscope. Double-positive cells were identified as differentiating EPCs.

GLP-1 treatment of EPCs

EPCs were pretreated with and without different concentrations of GLP-1 1,10,20 nM for 72 h. Three groups of EPCs were treated with VEGF (Sigma) 10, 20,30ng/ml, an important cytokine in the process of vascular endothelial cell differentiation and maturation. To further confirm the role of VEGF in EPCs biology, 1 group of EPCs was treated with 5 µmol/l SU1498 (Sigma), a specific inhibitor of KDR signaling pathway. Another group of EPCs was treated with anti-VEGFrnmAb (Sigma) 100 ng/ml.

EPCs proliferation

Adherent cells were detached by 0.25% trypsin solution and collected 500 µl cell suspension to count cell number. EPCs were plated in 96-well human fibronectin-coated plates and 10 µl MTT (Sino-American Biotechnology Co) at 5mg/ml were added into each well and incubated for 4 hours at 37 degrees Celsius. EPCs proliferation was sampled every other cycle and electrophoresed on 15 µmol/l agarose gel. Belts were observed and photos were taken by a gel image analysis system. GAPDH was calculated as a reference, the stained cells were viewed with a laser scanning confocal microscope. Double-positive cells were identified as differentiating EPCs.

RT-PCR polymerase chain reaction assay

RNA was harvested with Trizol kit (Sigma) from cell according to the manufacturer’s instructions, mRNA was reverse transcribed to cDNA with the RNA PCR Core kit (Sino-American Biotechnology Co). Primer sequences are the following: GAPDH forward: 5'-CCCATCACCACCTTCCAGGAG-3', reverse: 5'-CCCTGCTCACCACCTTCCAGGAG-3'; Flt-1 forward: 5'-ATCTTGTGATT1TTTGGCCTTGGGATTGC-3', reverse: 5'-CAGGGTCATGACTTGAAACG-3'; KDR forward: 5'-AGACCCAAAGGGGCACGATTG-3', reverse: 5'-CAGCAGAAACCAAGACGCCAGAC-3'; VE-cadherin forward: 5'-GGCTGAGGAAGAAAAACAGAAGAAGC-3', reverse: 5'-TCGTGATATATCCCTGAGGGAAGTAAAG-3'; eNOS forward: 5'-AGCGAGTGGACGCAAGC-3', reverse: 5'-TCCACGGGAAGCAGGAAAGG-3'. The amplified product was sampled every other cycle and electrophoresed on 15 g/L agarose gel. Bands were observed and photos were taken by a gel image analysis system. GAPDH was calculated as a parameter of relative mRNA levels. The PCR primers were synthesized by Shanghai Sangon Biological Engineering Technology Co.

Measurement of VEGF in EPCs

VEGF in cell-culture medium was measured using the commercially available VEGF sandwich immunoassay kit (Quantikine human VEGF ELISA kits [R&D Systems] according to the manufacturer’s instructions. The cell smears were obtained after centrifugation of EPCs and fixed with 4% paraformaldehyde for 30 min. SP immunocytochemistry was carried out to determine the VEGF protein levels according to the manufacturer’s instructions (Santa Cruz Biotechnology). Images of the stained cells
were viewed with inverted microscope and analyzed by the Medical Image Analysis system (HMIA S-2000).

**Statistical analysis**

The data were generally expressed as means ±SD. SPSS software version 11.0 was used for statistical analyses. Statistical significance among mean values was evaluated by one-way ANOVA tests for measurement data, and LSD-t test for comparison between each other. Differences were considered significant when p value was less than 0.05.

**RESULTS**

**Characterization of EPCs**

EPCs were originated from peripheral blood MNCs of healthy subjects as previously described. EPCs were cultured on fibronectin, a fraction of cells adhered to fibronectin, whereas others still suspended in culture medium (Figure 1A). Numerous spindle-shaped cells were observed 7 days in culture (Figure 1B). On day 14 of culture the majority of typical spindle-shaped endothelial-like cells were found and connected end-to-end to exhibit cord-like structure (Figure 1C).

**Identification of EPCs**

After mononuclear cells were isolated from peripheral blood for 7 days, a laser scanning confocal microscope was used to detect the surface markers of adherent cells. Images of the double-staining cells for both CD133 and CD34 were viewed: positive cells for CD133 are red; positive cells for CD34 are green; yellow double-positive cells were identified as differentiating EPCs (Figure 1D). EPCs were further confirmed as cells double-positive for CD133 uptake and

---

**Figure 1. Morphology and characterization of endothelial progenitor cells (EPCs) from peripheral blood. (A) Mononuclear cells (MNCs) were isolated and plated on fibronectin-coated culture dish on the second day. (B) 7 days after plating, adherent EPCs with spindle-shape and cell colony were shown. (C) EPCs joined end to end exhibited cord-like structure. Identification of EPCs. (D) Double-positive for CD133 and CD34; (E) Double-positive for CD133 and KDR.
KDR binding affinity. Double-positive cells were identified as differentiating EPCs (Figure 1E). Laser scanning confocal microscope analysis revealed that EPCs expressed endothelial markers CD34 and KDR, which are considered critical markers of outgrowth endothelial cell-producing EPCs. Stem cell marker CD133 was still expressed.

GLP-1 increase proliferation of EPCs

After seeding MNCs on wells, cells were incubated with different concentrations of GLP-1 for 72 hours. The effect of GLP-1 on EPCs proliferation was analyzed by MTT assay. GLP-1 concentration dependently improved EPCs proliferation activity, which became apparent at 1nmol/l (Figure 2).

**Effects of GLP-1 on the expression of KDR, FLT-1, VE-cadherin eNOS mRNA in EPCs**

Next, we investigated GLP-1 capable of improving the functional capacity of differentiation of EPCs. KDR, Flt-1, VE-cadherin and eNOS are key EC-lineage markers. The mRNA levels of KDR, Flt-1, VE-cadherin and eNOS were determined by using RT-PCR. GLP-1 modulated the expression of these EC-specific markers in EPCs in a dose-dependent manner at 72 hours (Figure 3). Pretreatment with GLP-1 significantly increased the KDR, Flt-1, VE-cadherin and eNOS expression. These results indicate that GLP-1 accelerates the differentiation of EPCs into endothelial cells.

**GLP-1 augmented the VEGF generation**

EPCs generated and released VEGF by autocrine or paracrine, which play an important role in the process of vascular endothelial cell differentiation and maturation. We therefore investigated the effects of GLP-1 on VEGF generation in EPCs. As shown in Figure 4A and C, GLP-1 augmented the VEGF generation from EPCs. The concentration of VEGF in GLP-1 culture media on 72 hours was significantly greater in the GLP-1 group than in the control group. Immunocytochemical examination revealed that EPCs expressed VEGF protein intensively in GLP-1-conditioned EPCs (Figure 4C). Thus, GLP-1 significantly augmented VEGF production and release from EPCs during EPCs differentiation.
VEGF improve proliferation and differentiation of EPCs

To elucidate the role of VEGF released from EPCs on their self-differentiation, we examined the effects of exogenous rhVEGF in (10, 20, 30 ng/mL) on the proliferation and differentiation of EPCs [6]. Exogenous VEGF significantly enhanced the proliferation and expression of FLT-1, KDR, VE-cadherin, eNOS mRNA of EPCs.

Increase of VEGF autocrine plays an important role in the proliferation and differentiation of EPCs

To test our hypothesis that GLP-1 influences proliferation and differentiation of EPCs increase of VEGF, we examined the effects of the anti-VEGF mAb, the tyrosine kinase inhibitor genistein, and the KDR-specific receptor tyrosine kinase inhibitor, SU1498, on the activity of EPCs [9]. Both of these 2 agents potently inhibited the proliferation of EPCs preincubated with GLP-1. Moreover, the anti-VEGF mAb and SU1498 significantly suppressed FLT-1, KDR, VE-cadherin, and eNOS mRNA expression of EPCs cultured by GLP-1, indicating VEGF and KDR may mediate the improvement effect of GLP-1 on EPCs. GLP-1 downregulated EPCs by modulating VEGF secretion.

DISCUSSION

Previous studies have shown that GLP-1 secreted from the gut is an incretin that has diverse actions, including promotion of propagation and differentiation of pancreatic islet B cells, increased secretion of insulin, inhibition of food and water intake, gastric emptying, and stimulation of neuroendocrine responses characteristic of visceral illness [10, 11]. In the present study we demonstrated that exposure of cultured EPCs to GLP-1 improved the proliferation activity. KDR, Flt-1, VE-cadherin, and eNOS are key EC-lineage markers. In addition, a greater number of GLP-1-conditioned EPCs expressed EC-lineage markers, FLT-1, eNOS, VE-cadherin, and KDR compared with control.
suggesting that GLP-1 accelerates the differentiation of EPCs into endothelial cells. Studies indicated that endothelial function is correlated with the number of circulating EPCs [12,13]. It is thought that regulation of the number and function of EPCs directly influences the maintenance and development of atherosclerosis. It is clinically important to estimate the degree of EPCs bioactivity and to increase the EPCs bioactivity by appropriate interventions [14]. Thus, these results suggest that GLP-1 potentially improved the endothelial cell dysfunction via regulating EPCs. In agreement with our study, numerous findings suggest a role for GLP-1 cardiovascular protective effect. GLP-1 potentially improved the endothelial cell dysfunction associated with premature atherosclerosis identified in type 2 diabetic patients [15]. Furthermore, GLP-1 has antihypertensive and cardiac and renal protective effects in rats fed a high salt diet [16]. Infusion of GLP-1 in subjects with type 2 diabetes and stable coronary disease has shown beneficial effects on flow-mediated vasodilatation [17].

We next examined the potential mechanisms by which GLP-1 enhanced proliferation and differentiation of EPCs. It has been shown that EPCs and endothelial cells produced and released cytokine or growth factor by autocrine or paracrine, such as VEGF,CP-1,FGF,TGF1 [18]. We observed that EPCs intervened by GLP-1, VEGF mRNA expression, cellular VEGF and supernatant VEGF were increased markedly, demonstrating that GLP-1 improves VEGF autocrine or paracrine in EPCs. VEGF is an important cytokine in the process of vascular endothelial cell differentiation and maturation. The increase of VEGF autocrine induced by GLP-1 may in turn influence the classical process of angiogenesis, namely the proliferation, migration and survival of mature endothelial cells. Many studies have established that ectogenesis VEGF can promote the EPCs endothelial cell differentiation, which agrees with the present study. Our study also indicated that EPCs cultivated from different sources showed a marked expression of growth factors such as VEGF, HGF, and IGF-1 [19,20]. These results support the notion that GLP-1 improves the function of EPCs through upregulating VEGF generation.

To minimize the possibility that our observations were the result of nonspecific pharmacological effects, we employed anti-VEGF mAb and exogenous VEGF to elucidate the role of autocrine VEGF released from EPCs. First, anti-VEGF mAb, blocking the endogenic VEGF, potently suppressed the proliferation function of EPCs. Second, exogenous VEGF Enhanced both proliferation and differentiation activity of EPCs in a dose-dependent manner, consistent with the report that exogenous VEGF administration significantly enhanced the

![Figure 6](image-url)
determination of PB-MNCs into EPCs. Thus, by using anti-VEGFmAb and exogenous VEGF, our data conclusively demonstrates that GLP-1 results in increase of VEGF generation, which appears to mediate beneficial effects of GLP-1 on EPCs. These novel findings suggest that VEGF is potentially the key effector linking GLP-1 to the improvement of EPCs.

It has been suggested that VEGF elicits the endothelialization and angiogenic function in EPCs mainly through the receptor tyrosine kinase KDR and Flk-1. That is, VEGF induces EPCs proliferation and increases PB-MNCs differentiation into EPCs via the KDR/Flk-1. Moreover, FLT-1 and KDR are important markers of matured vascular endothelial cells [21]. Expression of the VEGF receptors KDR and Flt-1 in EPCs gradually increased with the duration of cell GLP-1 culture. These findings indicate that cells exposed to GLP-1 acquire enhanced responsiveness to endogenous VEGF. Studies have shown the VEGF-KDR signaling pathway also induces KDR expression as a positive feedback mechanism [22]. Thus, augmented VEGF release might have enhanced the expression of KDR on EPCs. To further clarify the mechanism, we tested the KDR-specific tyrosine kinase inhibitor SU1498 on the proliferation and differentiation of EPCs. SU1498 suppressed the proliferation and expression of EC-lineage markers. These findings clearly suggest that the VEGF generated from EPCs, and the VEGF signaling through the KDR receptor tyrosine kinase, play important roles in the differentiation of PB-MNCs into EPCs. Thus activation of KDR, as well as the increase in its expression, may be involved in the mechanism by which GLP-1 stimulates EPCs proliferation and differentiation activities.

Taken together, these results indicate that GLP-1 improves VEGF generation, which contributed to improvement of EPCs biological function, partly by tyrosine kinase KDR. VEGF is a necessary intermediate mediating the effects of GLP-1 on EPCs. These changes offer a novel explanation that upregulation EPCs bioactivities may be one of the mechanisms of GLP-1-cardiovascular protective effect.

REFERENCES:

1. Liu HB, Dear AE, Knudsen LB, Simpson RW: A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol, 2009; 201(1): 59-66
2. Asahara T, Murohara T, Sullivan A et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997; 275: 964-67
3. Balbarini A, Barsotti MC, Di Stefano R et al: Circulating endothelial progenitor cells characterization, function and relationship with cardiovascular risk factors. Curr Pharm Des, 2007; 13(16): 1699-713